10-Q
MEDICINES CO /DE filed this form 10-Q on 15 May 2002
- velhartice.info
<PAGE>

                              THE MEDICINES COMPANY
                 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (unaudited)



<TABLE>
<CAPTION>
                                                                   THREE MONTHS ENDED MARCH 31,
                                                                 -------------------------------
                                                                     2002               2001
                                                                 ------------       ------------
<S>                                                              <C>                <C>          
Cash flows from operating activities:
  Net loss                                                       $(11,641,306)      $(19,055,986)
    Adjustments to reconcile net loss to net cash
      used in operating activities:
    Depreciation                                                      132,367            104,829
    Amortization of deferred stock compensation                       984,611          1,120,932
    Loss on sales of fixed assets                                        --                  251
    Changes in operating assets and liabilities:
      Accrued interest receivable                                       6,743            209,400
      Accounts receivable                                          (1,309,747)        (1,792,124)
      Inventory                                                    (2,883,463)           (87,009)
      Prepaid expenses and other current assets                      (267,142)            69,762
      Other assets                                                     (1,395)          (212,102)
      Accounts payable                                              3,388,681         (2,280,050)
      Accrued expenses                                                397,841          1,885,622
      Deferred revenue                                              1,489,583               --
                                                                 ------------       ------------
        Net cash used in operating activities                      (9,703,227)       (20,036,475)

Cash flows from investing activities:
  Purchases of available for sale securities                             --           (1,457,913)
  Maturities and sales of available for sale securities                  --           10,926,379

  Purchase of fixed assets                                             (6,182)           (94,658)
                                                                 ------------       ------------
        Net cash provided by (used in) investing activities            (6,182)         9,373,808

Cash flows from financing activities:
  Proceeds from revolving line of credit borrowings                10,000,000               --
  Proceeds from sale of common stock, net                           1,285,554            171,472
  Repurchases of common stock                                            --                  (10)
                                                                 ------------       ------------
        Net cash provided by financing activities                  11,285,554            171,462
Effect of exchange rate changes on cash                                 3,546            (11,940)
                                                                 ------------       ------------
Increase (decrease) in cash and cash equivalents                    1,579,691        (10,503,145)
Cash and cash equivalents at beginning of period                   53,884,376         36,802,356
                                                                 ------------       ------------
Cash and cash equivalents at end of period                       $ 55,464,067       $ 26,299,211
                                                                 ============       ============
</TABLE>




     See accompanying notes to condensed consolidated financial statements.


                                     Page 3